After a 2007 MRI scan, a 70-year-old dialysis patient is planning to sue a Boston hospital after developing nephrogenic systemic fibrosis, or NSF.

The gadolinium-based agent improves and clarifies MRI scans. However, for patients with kidney issues, namely those on dialysis, the risk of developing NSF is increased to dangerous levels. The Food & Drug Administration has given the scanning agent their black box label, the highest warning the agency issues for potentially dangerous drugs. 

The woman was given the agent to improve her MRI scans at King Edward VII Memorial Hospital and Brighan and Women's Hospital in Boston in 2007. Since then, the woman has contracted the skin disorder. Her husband believes that the hospital staff and doctors should have known not to use gadolinium-based agents, especially considering the FDA's strict warnings especially directed to patients with kidney problems.

The hospital announced that it will try to reconcile grievances between the medical staff and family.

There is currently no cure or successful treatment for NSF.

If you have suffered adverse side-effects due to gadolinium-based agents, you may be eligible for compensation. Contact the nephrogenic systemic fibrosis attorneys of Williams Kherkher by calling 800-761-3187 today to discuss your claim.

Bayer HealtCare Pharmaceuticals as announced their results of a recent medical trial of a new GBCA, or gadolinium-based contrast agent.

Gadobutrol, the drug under investigation, has not yet been approved by the Food & Drug Administration, as these trials, said the company, are entirely for the process of developing the new drug.

While the company assured those involved in the process, that no serious adverse effects came from the study and that only about 4% of the patients in the study suffered any adverse effects at all, they did recognize that the drug does not defy the FDA warning mandated in May 2007. The warning is meant to inform patients that GBCAs, which are used in MRIs for better imaging results, can also cause Nephrogenic Systemic Fibrosis, which can lead to serious impairment and even death.

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

Gadolinium usually is injected into the circulatory system. The injection allows doctors to better diagnose the MRI scan. 

After the MRI is administered, the gadolinium typically is filtered out of the body. However, for people with serious kidney problems, the gadolinium may filter out slowly or stay for a long period of time. The increased exposure to gadolinium may increase the chances of contracting Nephrogenic Systemic Fibrosis. 

If you or anyone you know has suffered Nephrogenic Systemic Fibrosis after gadolinium exposure, contact the Gadolinium lawyers of Williams Kherkher at 800-761-3187.

The FDA has approved a number of gadolinium-based contrast agents. These contrast agents include Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. 

While the use of these drugs has been associated with NSF, they still have FDA approval. One reason for maintaining this approval is that medical reports have not gathered enough information about the correlation between gadolinium and NSF. 

If you have beeen diagnosed with NSF and been exposed to a gadolinium-based contrast agent, contact the gadolimium lawyers of Williams Kherkher at 800-761-3187.

An FDA-appointed panel has ruled that restrictions should be placed on the use of gadolinium contrast agents (commonly used in medical imaging scans) after convincing evidence has linked the agents to a potentially fatal skin-hardening disease called nephrogenic systemic fibrosis (NSF). Sources say that NSF is a progressive disease that can cause the skin to thicken and harden in the arms, legs, and extremities.

While the FDA does not have to follow the advice of it's appointed panels, sources say that a panel recommendation often goes a long way toward implementing new regulations. 

If you or someone you love has suffered NSF or other health problems caused by gadolinium contrast agents, contact the NSF attorneys of Williams Kherkher at 800-761-3187 today.

Optimark will undergo a voluntarily label change to notify users of the risks associated with the product. According to MSN's Market Report, Covidien announced that it will contraindicate the Optimark gadovesetamide injection. 

The injection is used as a gadolinium-based contrast agent for magnetic resonance imaging procedures. While some label changes are voluntary, gadolinium-based contrast agents have been associated with mandatory label changes in the past to inform patients about the risks. 

If you or anyone you know has suffered negative side effects as a result of being injected with a gadolinium-based contrast agent, contact the NSF and NFD lawyers of Williams Kherkher at 800-761-3187.